Format

Send to

Choose Destination
Indian J Med Microbiol. 2019 Jan-Mar;37(1):91-94. doi: 10.4103/ijmm.IJMM_19_207.

Bad bug, no test: Tigecycline susceptibility testing challenges and way forward.

Author information

1
Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, India.

Abstract

Tigecycline is a reserve antibiotic increasingly used for the treatment of multidrug-resistant bacteria, especially Klebsiella pneumoniae and Acinetobacter baumannii. At present, there are concerns regarding the testing and interpretation of tigecycline susceptibility to bugs such as K. pneumoniae and A. baumannii, which limit clinicians in appropriate usage. Use of appropriate method for testing such as broth microdilution is essential. In addition, tigecycline susceptibility testing is a challenge due to inconsistent results from various antimicrobial susceptibility testing automated platforms. There is a great need to define a suitable methodology along with interpretive criteria, especially for K. pneumoniae and A. baumannii. The European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Food and Drug Administration (FDA) breakpoints show wide variation and are defined for different set of organisms. Non-species-related pharmacokinetic/pharmacodynamic (PK/PD) breakpoints defined by the EUCAST can be used for organisms such as K. pneumoniae and A. baumannii.

KEYWORDS:

Acinetobacter baumannii; European Committee on Antimicrobial Susceptibility Testing; Klebsiella pneumoniae; interpretation; tigecycline

PMID:
31424015
DOI:
10.4103/ijmm.IJMM_19_207
Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center